Baclofin and Alcohol Use Disorder

Baclofin was originally approved for treatment of muscle spasticity, but more recently has come onto the radar for alcohol use disorder treatment. The Cochrane review showed that baclofin reduces relapse compared with placebo and is associated with higher frequency of adverse events. One in five experienced parastasia, one in nine somnolins, one in 10 dizziness,. and they saw a number needed to harm for fatigue of 12.